This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Baxter Stock May Gain Following Five New Injectable Product Launches
by Zacks Equity Research
BAX launches five new injectible products in the United States, thus further strengthening its U.S Pharmaceuticals business segment.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM continues to raise optimism among investors owing to its strong product portfolio.
Here's Why You Should Hold Cencora Stock in Your Portfolio for Now
by Zacks Equity Research
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Reasons to Retain PacBio Stock in Your Portfolio for Now
by Zacks Equity Research
PACB continues to deliver growth from its unique technologies amid business seasonality concerns.
MBOT Stock Gains Following FDA Submission of the LIBERTY System
by Zacks Equity Research
Microbot Medical announces the submission of its LIBERTY System for FDA marketing clearance.
NSPR Stock May Gain as First Patient Enrolls in CGUARDIANS II Study
by Zacks Equity Research
InspireMD announces the first patient enrolment in the CGUARDIANS II clinical trial.
Here's Why You Should Add Glaukos Stock to Your Portfolio Now
by Zacks Equity Research
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Hologic Trades at 17.62X P/E: Should You Buy, Sell or Hold the Stock?
by Moumi Mondal
Despite the current challenges, HOLX's portfolio strength and international growth prospects make it worth holding on to.
Here's Why You Should Add Accuray Stock in Your Portfolio Now
by Zacks Equity Research
ARAY's solid product demand and revenue growth raise optimism about the stock.
HealthEquity Stock Falls Despite Q3 Earnings and Revenue Beat
by Zacks Equity Research
HQY's fiscal third-quarter results benefit from robust HSA growth and improved gross margin. It also raises fiscal 2025 guidance.
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now
by Zacks Equity Research
XRAY continues to gain traction from a robust product portfolio. However, the suspension of Byte's business and macroeconomic factors, such as weakened global demand, persist.
ZYXI Stock Gains on the Completion of NiCO's Clinical Verification Trial
by Zacks Equity Research
Zynex announces the completion of the clinical verification trial of its NiCO pulse oximeter.
Veeva Systems Q3 Earnings & Revenues Beat, Operating Margin Up Y/Y
by Zacks Equity Research
VEEV's fiscal third-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.
Why Is Steris (STE) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stryker Gains 30.2% Year to Date: What's Driving the Stock?
by Zacks Equity Research
SYK continues to witness growth on the back of a robust product line and strategic acquisitions.
GEHC Stock May Gain Following the Launches of Aurora and Clarify DL
by Zacks Equity Research
GE HealthCare announces that Aurora will expand the range of CT procedures and Clarify DL will enhance SPECT image quality.
Strength Across Segments to Help CAH Stock Offset OptumRx Headwind?
by Zacks Equity Research
CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, concentrated revenue generation and regulatory setbacks are a concern.
GEHC Stock May Gain From Potential FDA Clearance for CleaRecon DL
by Zacks Equity Research
GE HealthCare announces the FDA submission of its CleaRecon DL technology to improve CBCT images.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL continues to witness growth on the back of its strong product portfolio.
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
by Zacks Equity Research
NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.
NARI Stock Likely to Gain Following Reimbursement Approval in Japan
by Zacks Equity Research
Inari Medical announces reimbursement approval for ClotTriever Thrombectomy System in Japan and a new distribution partnership with Medikit.
GEHC Stock May Gain Following the Launch of Sonic DL for 3D Imaging
by Zacks Equity Research
GE HealthCare announces the new Sonic DL for 3D, which will reduce scan times and provide faster, high-quality imaging for the majority of MR scans.
The Zacks Analyst Blog Highlights MACOM Technology Solutions, Masimo, Leonardo DRS, Ingredion and Carpenter
by Zacks Equity Research
MACOM Technology Solutions, Masimo, Leonardo DRS, Ingredion and Carpenter are included in this Analyst Blog.
Buy 5 Mid-Cap Stocks Poised to Turn Into Large Caps in 2025
by Nalak Das
These mid-cap stocks have the potential to become large-caps in 2025. These are: MTSI, MASI, DRS, CRS, INGR.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
by Zacks Equity Research
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.